Single-drug oral antibacterial prophylaxis with ofloxacin in BMT recipients.

We evaluated the efficacy and safety of a new oral fluoroquinolone, ofloxacin (200 mg twice lily), as antibacterial prophylaxis after BMT in a non-comparative prospective study of patients nursed in either LAF plastic isolators or HEPA filtered single rooms. Of the 101 evaluable patients who were neutropenic (<500× 10 6 /l) for a median duration of 20 days, 92 (91%) had febrile episodes of varying length and causes. Infections were documented in 34 patients, of whom 14 had proven bacterial infection (13 with bacteremia and one with pneumonia). Mortality rate within 6 weeks after transplant was 6%. Only one patient died from bacterial infection